综合生物信息学和功能研究确定CDK9作为潜在的预后生物标志物和AML治疗点
Zhibin Xie1, Yang Xia2, Zhongyu Li3
1Department of Hematology, First Affiliated Hospital of Bengbu Medical University, Bengbu, 233003, Anhui, China.
Discover oncology
|June 9, 2025
概括
循环素依赖性激酶9 (CDK9) 在急性髓性白血病 (AML) 中升高,并与预后不佳有关. 向CDK9为改善AML治疗疗效和患者存活率提供了一个潜在的新策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 急性髓性白血病 (AML) 是一种复杂的血液癌症,结果不佳.
- 确定新的治疗点对于改善AML治疗至关重要.
- 循环素依赖性激酶9 (CDK9) 调节基因表达,并在AML中进行了研究.
研究的目的:
- 研究CDK9在AML病变和预后中的作用.
- 评估CDK9作为潜在的预后生物标志物和AML的治疗点.
主要方法:
- 使用生物信息数据库 (TIMER2.0,TCGA,GTEx) 来分析CDK9在AML中的表达.
- 进行生存和考克斯回归分析以评估预后意义.
- 进行了途径分析 (GO,KEGG,GSEA) 并评估了免疫细胞透.
- 通过体外实验验验证的结果 (西式涂抹,CCK-8,流细胞计).
主要成果:
- 在AML中,CDK9的表达显著升高,与预后不佳相关.
- CDK9与细胞增殖,分化和瘤微环境有关.
- CDK9的表达与改变的免疫细胞透和上皮-介质细胞过渡 (EMT) 有关.
- 过度表达CDK9促进AML细胞增殖,并在体外抑制细胞亡.
结论:
- CDK9是一种潜在的预后生物标志物和AML的治疗点.
- CDK9影响关键的AML发展途径和瘤免疫微环境.
- 向CDK9需要进一步调查,以改善AML治疗结果.
更多相关视频
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
5.6K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
39
相关概念视频
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
